• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CRO QPS acquires Qualitix

CRO QPS acquires Qualitix

March 9, 2011
CenterWatch Staff

QPS, a global GLP/GCP-compliant CRO providing testing services for preclinical and clinical R&D, has acquired a majority interest of Qualitix Clinical Research. Qualitix, a spin-off of Taiwan-based biotech Genovate, is a CRO and site management organization (SMO) with offices in Taiwan and China. Genovate will retain a minority interest in Qualitix, which will be known as QPS-Qualitix Taiwan.

QPS’s areas of expertise include toxicology, DMPK, bioanalytical, translational medicine, early-stage and late-stage clinical research.  Qualitix offers research development services to clients in pharmaceutical, biotechnology and medical device industries engaged in new drug development and phase I-IV multinational clinical trials.

The QPS-Qualitix merger will also involve ownership of a subsidiary corporation called Unitix, an SMO that handles QPS-Qualitix patient recruitment in the region.

"We are very happy to partner with QPS. This partnership will not only allow Qualitix to vertically integrate with QPS for more global exposure and market competitiveness, but also offer complete services from preclinical to clinical to expedite new drug development," said Dr. Jen Chen, CEO of Genovate.

"This expansion in phase I-IV clinical capability dovetails with our recent preclinical facility acquisition here in Taiwan," said Vincent Yen, president and CEO of QPS-Taiwan.

 

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing